Saunders R L
South Med J. 1977 Nov;70(11):1327-9.
A 46-year-old woman with the CRST variant of scleroderma (calcinosis, Raynaud's phenomenon, sclerodactyly, and telangiectasis) was treated with a diphosphonate (disodium etidronate) in an effort to reduce her dystrophic calcifications or retard their progression. After 18 months of therapy, no improvement in her calcinosis was noted. In addition, she developed bloody diarrhea, epigastric burning, and weight loss during the last two months of Therapy. Upper gastrointestinal series revealed a gastric ulcer. Endoscopy with biopsy proved it to be benign. Gastric ulcerations has been seen in animals given disodium etidronate but only at much higher doses than are currently recommended for humans. Although a cause and effect relationship cannot be established with certainty in this patient, it is suggested since she was not receiving other ulcerogenic drugs chronically. This information may be important to other investigators of disodium etidronate.
一名患有硬皮病CRST变异型（钙质沉着、雷诺现象、指（趾）硬皮病和毛细血管扩张）的46岁女性接受了双膦酸盐（依替膦酸二钠）治疗，以减少其营养不良性钙化或延缓其进展。治疗18个月后，未发现其钙质沉着有改善。此外，在治疗的最后两个月，她出现了血性腹泻、上腹部烧灼感和体重减轻。上消化道造影显示有胃溃疡。内镜检查及活检证实为良性。给动物服用依替膦酸二钠时曾出现胃溃疡，但所用剂量远高于目前推荐给人类的剂量。虽然在该患者中不能确定建立因果关系，但由于她未长期服用其他致溃疡药物，故提示可能有关。该信息对其他研究依替膦酸二钠的研究人员可能很重要。
